| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | -0.036 | 0.2 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | 0.04 | 0.2 |
| mRNA | BRD-K86535717 | CTRPv2 | pan-cancer | AAC | -0.082 | 0.2 |
| mRNA | ZG-10 | GDSC1000 | pan-cancer | AAC | -0.053 | 0.2 |
| mRNA | Compound 7d-cis | CTRPv2 | pan-cancer | AAC | -0.042 | 0.2 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.037 | 0.2 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.039 | 0.2 |
| mRNA | GSK525762A | CTRPv2 | pan-cancer | AAC | -0.034 | 0.2 |
| mRNA | BMS-754807 | GDSC1000 | pan-cancer | AAC | 0.04 | 0.2 |
| mRNA | thapsigargin | GDSC1000 | pan-cancer | AAC | -0.042 | 0.3 |